Literature DB >> 28343418

Epigenetic factors as drivers of fibrosis in systemic sclerosis.

Christina Bergmann1, Jörg Hw Distler1.   

Abstract

Prolonged activation of fibroblasts is a central hallmark of fibrosing disorders such as systemic sclerosis (SSc). Fibroblasts are the key effector cells. They differentiate into an activated myofibroblast phenotype. In contrast to normal wound healing with transient activation, myofibroblasts persist in fibrosing disorders. Current hypothesis suggests that profibrotic cytokines might trigger epigenetic changes which contribute to the persistently activated fibroblast phenotype. In the last years, several epigenetic alterations have been described in SSc and have been linked to different pathogenic aspects of the disease, in particular to aberrant fibroblast activation and tissue fibrosis, but also to vascular manifestations and inflammation. The focus of this review is the current knowledge on epigenetic changes in fibroblast activation in SSc.

Entities:  

Keywords:  DNA-methylation; epigenetics; histone modification; myofibroblast differentiation; noncoding RNA; systemic sclerosis

Mesh:

Substances:

Year:  2017        PMID: 28343418     DOI: 10.2217/epi-2016-0150

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  10 in total

1.  [New molecular mechanisms in the pathophysiology of rheumatic diseases].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2018-11       Impact factor: 1.372

2.  TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis.

Authors:  Clara Dees; Sebastian Pötter; Yun Zhang; Christina Bergmann; Xiang Zhou; Markus Luber; Thomas Wohlfahrt; Emmanuel Karouzakis; Andreas Ramming; Kolja Gelse; Akihiko Yoshimura; Rudolf Jaenisch; Oliver Distler; Georg Schett; Jörg Hw Distler
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 3.  Epigenetics of scleroderma: Integrating genetic, ethnic, age, and environmental effects.

Authors:  Paula S Ramos
Journal:  J Scleroderma Relat Disord       Date:  2019-07-03

4.  Therapeutic molecular targets of SSc-ILD.

Authors:  Yun Zhang; Jörg Hw Distler
Journal:  J Scleroderma Relat Disord       Date:  2020-01-22

Review 5.  Novel role of long non-coding RNAs in autoimmune cutaneous disease.

Authors:  Anastasiya Muntyanu; Michelle Le; Zainab Ridha; Elizabeth O'Brien; Ivan V Litvinov; Philippe Lefrançois; Elena Netchiporouk
Journal:  J Cell Commun Signal       Date:  2021-08-03       Impact factor: 5.782

6.  Epigenetic Regulation of Myofibroblast Phenotypes in Fibrosis.

Authors:  Thu Elizabeth Duong; James S Hagood
Journal:  Curr Pathobiol Rep       Date:  2018-03-16

Review 7.  Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.

Authors:  Chang-Youh Tsai; Song-Chou Hsieh; Tsai-Hung Wu; Ko-Jen Li; Chieh-Yu Shen; Hsien-Tzung Liao; Cheng-Han Wu; Yu-Min Kuo; Cheng-Shiun Lu; Chia-Li Yu
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

Review 8.  The role of TGF-β or BMPR2 signaling pathway-related miRNA in pulmonary arterial hypertension and systemic sclerosis.

Authors:  Bei Xu; Guanhua Xu; Ye Yu; Jin Lin
Journal:  Arthritis Res Ther       Date:  2021-11-25       Impact factor: 5.156

9.  Metallopeptidades 2 and 9 genes epigenetically modulate equine endometrial fibrosis.

Authors:  Joana Alpoim-Moreira; Carina Fernandes; Jorge Pimenta; Miguel Bliebernicht; Maria Rosa Rebordão; Pedro Castelo-Branco; Anna Szóstek-Mioduchowska; Dariusz J Skarzynski; Graça Ferreira-Dias
Journal:  Front Vet Sci       Date:  2022-08-12

Review 10.  Shared and distinct mechanisms of fibrosis.

Authors:  Jörg H W Distler; Andrea-Hermina Györfi; Meera Ramanujam; Michael L Whitfield; Melanie Königshoff; Robert Lafyatis
Journal:  Nat Rev Rheumatol       Date:  2019-11-11       Impact factor: 20.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.